par Pieters, Rob;Schrappe, Martin;De Lorenzo, Paola;Hann, Ian;De Rossi, Giulio;Felice, Maria;Hovi, Liisa;Leblanc, Thierry;Szczepanski, Tomasz;Ferster, Alina 
;Janka, Gritta;Rubnitz, Jeffrey;Silverman, Lewis B;Stary, Jan;Campbell, Myriam;Li, Chi Kong;Mann, Georg;Suppiah, Ram;Biondi, Andrea;Vora, Ajay;Valsecchi, Maria Grazia
Référence Lancet, 370, 9583, page (240-250)
Publication Publié, 2007-07
;Janka, Gritta;Rubnitz, Jeffrey;Silverman, Lewis B;Stary, Jan;Campbell, Myriam;Li, Chi Kong;Mann, Georg;Suppiah, Ram;Biondi, Andrea;Vora, Ajay;Valsecchi, Maria GraziaRéférence Lancet, 370, 9583, page (240-250)
Publication Publié, 2007-07
Article révisé par les pairs
| Résumé : | Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children. We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants. We also did a randomised trial to establish the value of a late intensification course. |
